Cantor Fitzgerald reiterated their overweight rating on shares of Alumis (NASDAQ:ALMS - Free Report) in a report released on Thursday,Benzinga reports.
A number of other analysts have also recently issued reports on the company. Morgan Stanley assumed coverage on Alumis in a research report on Tuesday, July 23rd. They set an "overweight" rating and a $36.00 price objective on the stock. Leerink Partnrs upgraded shares of Alumis to a "strong-buy" rating in a research report on Tuesday, July 23rd. Robert W. Baird assumed coverage on shares of Alumis in a research note on Thursday, October 31st. They set an "outperform" rating and a $25.00 price target for the company. Baird R W upgraded Alumis to a "strong-buy" rating in a research note on Thursday, October 31st. Finally, Leerink Partners assumed coverage on Alumis in a research report on Tuesday, July 23rd. They set an "outperform" rating and a $29.00 target price for the company. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Alumis currently has an average rating of "Buy" and an average price target of $26.83.
Get Our Latest Report on Alumis
Alumis Price Performance
NASDAQ:ALMS traded down $1.40 during trading hours on Thursday, hitting $9.41. 246,426 shares of the company traded hands, compared to its average volume of 151,332. Alumis has a twelve month low of $9.11 and a twelve month high of $13.53. The stock's 50-day moving average price is $11.33.
Alumis (NASDAQ:ALMS - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($21.53). As a group, equities research analysts anticipate that Alumis will post -8 EPS for the current year.
Institutional Trading of Alumis
Several hedge funds and other institutional investors have recently bought and sold shares of the business. SR One Capital Management LP bought a new position in Alumis during the 2nd quarter worth $26,067,000. Yu Fan purchased a new stake in shares of Alumis in the second quarter worth approximately $10,502,000. Ally Bridge Group NY LLC bought a new stake in Alumis in the 2nd quarter worth about $8,229,000. Towerview LLC lifted its holdings in Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company's stock worth $4,058,000 after acquiring an additional 70,000 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Alumis during the 2nd quarter valued at approximately $3,376,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
